Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 184 articles:
HTML format



Single Articles


    July 2021
  1. LEFRERE H, Floris G, Schmidt MK, Neven P, et al
    Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome.
    Eur J Cancer. 2021;155:13-24.
    PubMed     Abstract available


  2. HE J, Fu F, Wang W, Xi G, et al
    Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer.
    Eur J Cancer. 2021;154:217-226.
    PubMed     Abstract available


  3. YAMADA A, Kumamaru H, Shimizu C, Taira N, et al
    Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.
    Eur J Cancer. 2021;154:157-166.
    PubMed     Abstract available


  4. LE DU F, Dieras V, Curigliano G
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
    Eur J Cancer. 2021;154:175-189.
    PubMed     Abstract available


  5. HARTKOPF AD, Brucker SY, Taran FA, Harbeck N, et al
    Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
    Eur J Cancer. 2021;154:128-137.
    PubMed     Abstract available


  6. ARUN BK, Han HS, Kaufman B, Wildiers H, et al
    Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
    Eur J Cancer. 2021;154:35-45.
    PubMed     Abstract available


  7. YUAN Y, Lee JS, Yost SE, Frankel PH, et al
    Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
    Eur J Cancer. 2021;154:11-20.
    PubMed     Abstract available


    June 2021
  8. MUELLER V, Wardley A, Paplomata E, Hamilton E, et al
    Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
    Eur J Cancer. 2021;153:223-233.
    PubMed     Abstract available


  9. MARME F, Solbach C, Michel L, Schneeweiss A, et al
    Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2021;153:203-212.
    PubMed     Abstract available


  10. GUARNERI V, Dieci MV, Griguolo G, Miglietta F, et al
    Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
    Eur J Cancer. 2021;153:133-141.
    PubMed     Abstract available


  11. O'SHAUGHNESSY J, Sousa S, Cruz J, Fallowfield L, et al
    Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    Eur J Cancer. 2021;152:223-232.
    PubMed     Abstract available


  12. FURLANETTO J, Marme F, Seiler S, Thode C, et al
    Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Eur J Cancer. 2021;152:193-203.
    PubMed     Abstract available


  13. BOTTERI E, Baker JG, Sloan EK
    Response to the letter Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021 Jun 4. pii: S0959-8049(21)00268.
    PubMed    


  14. LYNCH SM, Russell NM, Barron S, Wang CA, et al
    Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Eur J Cancer. 2021;152:78-89.
    PubMed     Abstract available


  15. GELMON KA, Fasching PA, Couch FJ, Balmana J, et al
    Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Eur J Cancer. 2021;152:68-77.
    PubMed     Abstract available


    May 2021
  16. WOJTYLA C, Bertuccio P, Wojtyla A, La Vecchia C, et al
    European trends in breast cancer mortality, 1980-2017 and predictions to 2025.
    Eur J Cancer. 2021;152:4-17.
    PubMed     Abstract available


  17. DE SANCTIS R, Vigano A, Torrisi R, Santoro A, et al
    Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients: Sympathetic nervous system activity on breast cancer: the story of migraine.
    Eur J Cancer. 2021 May 27. pii: S0959-8049(21)00266.
    PubMed    


  18. KIM HJ, Noh WC, Nam SJ, Park BW, et al
    Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Eur J Cancer. 2021;151:190-200.
    PubMed     Abstract available


  19. LUFTNER D, Tesch H, Schmidt M, Hartkopf AD, et al
    Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
    Eur J Cancer. 2021;150:268-277.
    PubMed     Abstract available


  20. ROGADO J, Gullon P, Obispo B, Serrano G, et al
    Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
    Eur J Cancer. 2021;148:58-60.
    PubMed    


    April 2021
  21. ETHIER JL, Anderson GM, Austin PC, Clemons M, et al
    Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.
    Eur J Cancer. 2021;149:117-127.
    PubMed     Abstract available


    March 2021
  22. PEREZ-GARCIA JM, Llombart-Cussac A, G Cortes M, Curigliano G, et al
    Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase trial.
    Eur J Cancer. 2021;148:382-394.
    PubMed     Abstract available


  23. VILLEGAS SL, Nekljudova V, Pfarr N, Engel J, et al
    Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Eur J Cancer. 2021;148:159-170.
    PubMed     Abstract available


  24. QUINTANA A, Peg V, Prat A, Moline T, et al
    Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.
    Eur J Cancer. 2021;148:134-145.
    PubMed     Abstract available


  25. MICHAELSON-COHEN R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, et al
    Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Eur J Cancer. 2021;148:95-102.
    PubMed     Abstract available


  26. HOUSSAMI N, Zackrisson S, Blazek K, Hunter K, et al
    Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening.
    Eur J Cancer. 2021;148:14-23.
    PubMed     Abstract available


  27. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [Eur J Canc 144 (2021) 341-350].
    Eur J Cancer. 2021 Mar 7. pii: S0959-8049(21)00071.
    PubMed    


  28. PETRELLI F, Parati MC, Borgonovo K, Cabiddu M, et al
    Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies.
    Eur J Cancer. 2021;147:151-153.
    PubMed    


    February 2021
  29. JIANG M, Li CL, Luo XM, Chuan ZR, et al
    Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Eur J Cancer. 2021;147:95-105.
    PubMed     Abstract available


  30. GILLIS RD, Botteri E, Chang A, Ziegler AI, et al
    Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021;147:106-116.
    PubMed     Abstract available


    January 2021
  31. FURLANETTO J, Mobus V, Schneeweiss A, Rhiem K, et al
    Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2021;145:44-52.
    PubMed     Abstract available


  32. ROBERTSON JFR, Paridaens RJ, Lichfield J, Bradbury I, et al
    Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2021;145:19-28.
    PubMed     Abstract available


  33. DUBSKY P, Tausch C
    Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by Pfob et al.
    Eur J Cancer. 2021;143:178-179.
    PubMed    


  34. PATRIKIDOU A, Cathomas R
    Treading carefully in de-escalation for bone-targeted agents - is less more, after all?
    Eur J Cancer. 2021;142:141-142.
    PubMed    


  35. CLEMONS M, Ong M, Stober C, Ernst S, et al
    A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
    Eur J Cancer. 2021;142:132-140.
    PubMed     Abstract available


    December 2020
  36. R FERREIRA A, Ferreira S, Lambertini M, Maurer C, et al
    Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
    Eur J Cancer. 2020;144:351-359.
    PubMed     Abstract available


  37. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Eur J Cancer. 2020;144:341-350.
    PubMed     Abstract available


  38. BATTISTI NML, Reed MWR, Herbert E, Morgan JL, et al
    Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.
    Eur J Cancer. 2020;144:269-280.
    PubMed     Abstract available


  39. LAKSHMI S, Hughes TA, Priya S
    Exosomes and exosomal RNAs in breast cancer: A status update.
    Eur J Cancer. 2020;144:252-268.
    PubMed     Abstract available


  40. RIBELLES N, Jerez JM, Rodriguez-Brazzarola P, Jimenez B, et al
    Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
    Eur J Cancer. 2020;144:224-231.
    PubMed     Abstract available


  41. BOERS J, Venema CM, de Vries EFJ, Hospers GAP, et al
    Serial [(18)F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer.
    Eur J Cancer. 2020;144:151-161.
    PubMed     Abstract available


  42. GERRATANA L, Davis AA, Polano M, Zhang Q, et al
    Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
    Eur J Cancer. 2020;143:147-157.
    PubMed     Abstract available


  43. PFOB A, Sidey-Gibbons C, Lee HB, Tasoulis MK, et al
    Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy.
    Eur J Cancer. 2020;143:134-146.
    PubMed     Abstract available


  44. KOIVULUOMA S, Tervasmaki A, Kauppila S, Winqvist R, et al
    Exome sequencing identifies a recurrent variant in SERPINA3 associating with hereditary susceptibility to breast cancer.
    Eur J Cancer. 2020;143:46-51.
    PubMed     Abstract available


    November 2020
  45. DAFNI U, Martin-Lluesma S, Balint K, Tsourti Z, et al
    Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    Eur J Cancer. 2020;142:63-82.
    PubMed     Abstract available


  46. WYLD L, Reed MWR, Morgan J, Collins K, et al
    Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life.
    Eur J Cancer. 2020;142:48-62.
    PubMed     Abstract available


  47. COTTU P, Coudert B, Perol D, Doly A, et al
    Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018)
    Eur J Cancer. 2020;141:209-217.
    PubMed     Abstract available


  48. HUBEL K, Kron F, Lux MP
    Biosimilars in oncology: Effects on economy and therapeutic innovations.
    Eur J Cancer. 2020;139:10-19.
    PubMed     Abstract available


    October 2020
  49. STRADELLA A, Del Valle J, Rofes P, Vargas-Parra G, et al
    ERCC3, a new ovarian cancer susceptibility gene?
    Eur J Cancer. 2020;141:1-8.
    PubMed     Abstract available


  50. FINK MK
    Survival in metastatic breast cancer in the ESME study and the ATRESS effect.
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30495.
    PubMed    


  51. DELUCHE E, Antoine A, Bachelot T, Robain M, et al
    A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016".
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30490.
    PubMed    


    September 2020
  52. SALVADOR-COLOMA C, Santaballa A, Sanmartin E, Calvo D, et al
    Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Eur J Cancer. 2020;139:119-134.
    PubMed     Abstract available


    August 2020
  53. FRASCA M, Sabathe C, Delaloge S, Galvin A, et al
    Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016.
    Eur J Cancer. 2020;137:240-249.
    PubMed     Abstract available


  54. RETEL VP, Byng D, Linn SC, Jozwiak K, et al
    Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.
    Eur J Cancer. 2020;137:193-203.
    PubMed     Abstract available


  55. RATHOD S, Ahmed S, Vanstone R, Fatoye T, et al
    Working in the dark: Interaction with a sub clinical COVID-19 subject and lessons learned.
    Eur J Cancer. 2020;135:101-102.
    PubMed     Abstract available


    July 2020
  56. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020 Jul 14. pii: S0959-8049(20)30339.
    PubMed    


  57. HOWELL SJ, Keevil B, Higham C, Owen LJ, et al
    RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020 Jul 11. pii: S0959-8049(20)30338.
    PubMed    


  58. CONTE B, Bruzzone M, Lambertini M, Poggio F, et al
    Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
    Eur J Cancer. 2020;136:43-51.
    PubMed     Abstract available


  59. DIECI MV, Tsvetkova V, Griguolo G, Miglietta F, et al
    Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Eur J Cancer. 2020;136:7-15.
    PubMed     Abstract available


    June 2020
  60. STEENBRUGGEN TG, van Werkhoven E, van Ramshorst MS, Dezentje VO, et al
    Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
    Eur J Cancer. 2020;135:66-74.
    PubMed     Abstract available


  61. DUBSKY PC, Singer CF, Egle D, Wette V, et al
    The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
    Eur J Cancer. 2020;134:99-106.
    PubMed     Abstract available


    April 2020
  62. STJEPANOVIC N, Villacampa G, Nead KT, Torres-Esquius S, et al
    Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Eur J Cancer. 2020;132:53-60.
    PubMed     Abstract available


  63. SINGER CF, Pfeiler G, Hubalek M, Bartsch R, et al
    Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
    Eur J Cancer. 2020;132:43-52.
    PubMed     Abstract available


    March 2020
  64. WERUTSKY G, Untch M, Hanusch C, Fasching PA, et al
    Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.
    Eur J Cancer. 2020;130:92-101.
    PubMed     Abstract available


  65. ZAMANI P, Teymouri M, Nikpoor AR, Navashenaq JG, et al
    Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Eur J Cancer. 2020;129:80-96.
    PubMed     Abstract available


  66. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    PubMed     Abstract available


    January 2020
  67. FASTNER G, Sedlmayer F, Widder J, Metz M, et al
    Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.
    Eur J Cancer. 2020;127:12-20.
    PubMed     Abstract available


  68. DE BOO L, Cimino-Mathews A, Lubeck Y, Daletzakis A, et al
    Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    Eur J Cancer. 2020 Jan 16. pii: S0959-8049(19)30855.
    PubMed     Abstract available


  69. ZIELONKE N, Gini A, Jansen EEL, Anttila A, et al
    Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review.
    Eur J Cancer. 2020 Jan 10. pii: S0959-8049(19)30863.
    PubMed     Abstract available


  70. CLATOT F, Fontanilles M, Lefebvre L, Lequesne J, et al
    Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.
    Eur J Cancer. 2020;126:116-124.
    PubMed     Abstract available


  71. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020;126:104-105.
    PubMed    


  72. PONDE N, Amaye L, Lambertini M, Paesmans M, et al
    Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
    Eur J Cancer. 2020;126:65-73.
    PubMed     Abstract available


    December 2019
  73. BOERS J, Venema CM, de Vries EFJ, Glaudemans AWJM, et al
    Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
    Eur J Cancer. 2019;126:11-20.
    PubMed     Abstract available


  74. MIERZYNSKA J, Taye M, Pe M, Coens C, et al
    Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.
    Eur J Cancer. 2019;125:69-82.
    PubMed     Abstract available


  75. PASQUIER D, Darlix A, Louvel G, Fraisse J, et al
    Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
    Eur J Cancer. 2019;125:22-30.
    PubMed     Abstract available


    November 2019
  76. EVANS DG, Howell SJ, Howell A
    New evidence confirms that reproductive risk factors can be used to stratify breast cancer risks: Implications for a new population screening paradigm.
    Eur J Cancer. 2019 Nov 26. pii: S0959-8049(19)30775.
    PubMed    


  77. MUKAMA T, Fallah M, Tian Y, Sundquist K, et al
    Risk-tailored starting age of breast cancer screening based on women's reproductive profile: A nationwide cohort study.
    Eur J Cancer. 2019 Nov 21. pii: S0959-8049(19)30774.
    PubMed     Abstract available


    October 2019
  78. D'HONDT V, Canon JL, Roca L, Levy C, et al
    UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
    Eur J Cancer. 2019;122:91-100.
    PubMed     Abstract available


  79. ABDEL-AZIZ AK, Saadeldin MK, D'Amico P, Orecchioni S, et al
    Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.
    Eur J Cancer. 2019;122:22-41.
    PubMed     Abstract available


    September 2019
  80. DIAS AS, Almeida CR, Helguero LA, Duarte IF, et al
    Metabolic crosstalk in the breast cancer microenvironment.
    Eur J Cancer. 2019;121:154-171.
    PubMed     Abstract available


  81. TRUNTZER C, Isambert N, Arnould L, Ladoire S, et al
    Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer.
    Eur J Cancer. 2019;120:97-106.
    PubMed     Abstract available


  82. LLUCH A, Gonzalez-Angulo AM, Casadevall D, Eterovic AK, et al
    Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
    Eur J Cancer. 2019;120:54-64.
    PubMed     Abstract available


    August 2019
  83. ROBSON M, Ruddy KJ, Im SA, Senkus E, et al
    Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    Eur J Cancer. 2019;120:20-30.
    PubMed     Abstract available


  84. PIVOT X, Pegram M, Cortes J, Luftner D, et al
    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
    Eur J Cancer. 2019;120:1-9.
    PubMed     Abstract available


  85. HUOBER J, Holmes E, Baselga J, de Azambuja E, et al
    Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
    Eur J Cancer. 2019;118:169-177.
    PubMed     Abstract available


    July 2019
  86. GNANT M
    New evidence and hope for young patients with breast cancer.
    Eur J Cancer. 2019;118:166-168.
    PubMed    


  87. LE SAUX O, Lardy-Cleaud A, Frank S, Debled M, et al
    Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
    Eur J Cancer. 2019;118:131-141.
    PubMed     Abstract available


  88. OCHI T, Bianchini G, Ando M, Nozaki F, et al
    Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Eur J Cancer. 2019;118:41-48.
    PubMed     Abstract available


  89. DI COSIMO S, Triulzi T, Pizzamiglio S, De Cecco L, et al
    The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
    Eur J Cancer. 2019;118:1-9.
    PubMed     Abstract available


  90. MARTIN M, Loibl S, Hyslop T, De la Haba-Rodriguez J, et al
    Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Eur J Cancer. 2019;117:91-98.
    PubMed     Abstract available


    June 2019
  91. REBOLJ M, Blyuss O, Chia KS, Duffy SW, et al
    Long-term excess risk of breast cancer after a single breast density measurement.
    Eur J Cancer. 2019;117:41-47.
    PubMed     Abstract available


  92. CRISCITIELLO C, Curigliano G
    Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?
    Eur J Cancer. 2019;117:1-4.
    PubMed    


  93. KHINCHA PP, Best AF, Fraumeni JF Jr, Loud JT, et al
    Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome.
    Eur J Cancer. 2019;116:199-206.
    PubMed     Abstract available


  94. PERRONE F, De Laurentiis M, De Placido S, Orditura M, et al
    Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Eur J Cancer. 2019 Jun 1. pii: S0959-8049(19)30297.
    PubMed     Abstract available


    May 2019
  95. FROEHLICH K, Schmidt A, Heger JI, Al-Kawlani B, et al
    Breast cancer, placenta and pregnancy.
    Eur J Cancer. 2019;115:68-78.
    PubMed     Abstract available


  96. NOSKE A, Mobus V, Weber K, Schmatloch S, et al
    Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
    Eur J Cancer. 2019;114:76-88.
    PubMed     Abstract available


  97. MCCARTNEY A, Biagioni C, Schiavon G, Bergqvist M, et al
    Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
    Eur J Cancer. 2019;114:55-66.
    PubMed     Abstract available


    March 2019
  98. YUAN P, Hu X, Sun T, Li W, et al
    Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
    Eur J Cancer. 2019;112:57-65.
    PubMed     Abstract available


    February 2019
  99. EKHOLM M, Bendahl PO, Ferno M, Nordenskjold B, et al
    Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
    Eur J Cancer. 2019;110:53-61.
    PubMed     Abstract available


  100. ANDERSSON TM, Engholm G, Lund AQ, Lourenco S, et al
    Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
    Eur J Cancer. 2019;110:42-48.
    PubMed     Abstract available


    January 2019
  101. MONTEMURRO F, Ellis P, Anton A, Wuerstlein R, et al
    Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Eur J Cancer. 2019;109:92-102.
    PubMed     Abstract available


  102. YONEMORI K, Shimomura A, Yasojima H, Masuda N, et al
    A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
    Eur J Cancer. 2019;109:84-91.
    PubMed     Abstract available


  103. LIVI L, Scotti V, Desideri I, Saieva C, et al
    Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
    Eur J Cancer. 2019;108:100-110.
    PubMed     Abstract available


    December 2018
  104. SCHNEEWEISS A, Mobus V, Tesch H, Hanusch C, et al
    Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised
    Eur J Cancer. 2018;106:181-192.
    PubMed     Abstract available


  105. YE Z, Wang C, Wan S, Mu Z, et al
    Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
    Eur J Cancer. 2018;106:133-143.
    PubMed     Abstract available


    November 2018
  106. SINGER CF, Balmana J, Burki N, Delaloge S, et al
    Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
    Eur J Cancer. 2018;106:54-60.
    PubMed     Abstract available


  107. RUTGERS E, Balmana J, Beishon M, Benn K, et al
    European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer.
    Eur J Cancer. 2018;106:45-53.
    PubMed     Abstract available


  108. ZAMBETTI M, Montemurro F, Morandi P, Zamagni C, et al
    Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
    Eur J Cancer. 2018;105:61-70.
    PubMed     Abstract available


    October 2018
  109. HURVITZ SA, Quek RGW, Turner NC, Telli ML, et al
    Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
    Eur J Cancer. 2018;104:160-168.
    PubMed     Abstract available


  110. CRISTOFANILLI M, DeMichele A, Giorgetti C, Turner NC, et al
    Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Eur J Cancer. 2018;104:21-31.
    PubMed     Abstract available


    September 2018
  111. CAMPONE M, Lacroix-Triki M, Roca L, Spielmann M, et al
    UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
    Eur J Cancer. 2018;103:184-194.
    PubMed     Abstract available


  112. CAMPONE M, Im SA, Iwata H, Clemons M, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    Eur J Cancer. 2018;103:147-154.
    PubMed     Abstract available


  113. KIM JY, Im SA, Jung KH, Ro J, et al
    Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-la
    Eur J Cancer. 2018;103:127-136.
    PubMed     Abstract available


  114. VAN ROOIJEN JM, Qiu SQ, Timmer-Bosscha H, van der Vegt B, et al
    Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer.
    Eur J Cancer. 2018;103:52-60.
    PubMed     Abstract available


    August 2018
  115. VAN MAAREN MC, Strobbe LJA, Smidt ML, Moossdorff M, et al
    Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years.
    Eur J Cancer. 2018;102:82-94.
    PubMed     Abstract available


  116. VAN ROSSUM AGJ, Kok M, van Werkhoven E, Opdam M, et al
    Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
    Eur J Cancer. 2018;102:40-48.
    PubMed     Abstract available


  117. WITZEL I, Laakmann E, Weide R, Neunhoffer T, et al
    Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
    Eur J Cancer. 2018;102:1-9.
    PubMed     Abstract available


    July 2018
  118. VAN MAAREN MC, Lagendijk M, Tilanus-Linthorst MMA, de Munck L, et al
    Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.
    Eur J Cancer. 2018;101:134-142.
    PubMed     Abstract available


  119. RUGO HS, Turner NC, Finn RS, Joy AA, et al
    Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
    Eur J Cancer. 2018;101:123-133.
    PubMed     Abstract available


  120. BOUVARD B, Chatelais J, Soulie P, Hoppe E, et al
    Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Eur J Cancer. 2018;101:87-94.
    PubMed     Abstract available


  121. MAO H, Bao T, Shen X, Li Q, et al
    Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors.
    Eur J Cancer. 2018;101:47-54.
    PubMed     Abstract available


  122. DAVIS LE, Bubis LD, Mahar AL, Li Q, et al
    Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study.
    Eur J Cancer. 2018;101:1-11.
    PubMed     Abstract available


  123. BAO T, Seidman AD, Piulson L, Vertosick E, et al
    A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Eur J Cancer. 2018;101:12-19.
    PubMed     Abstract available


    June 2018
  124. GORI S, Puglisi F, Cinquini M, Pappagallo G, et al
    Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Eur J Cancer. 2018;99:9-19.
    PubMed     Abstract available


  125. DERKS MGM, Bastiaannet E, van de Water W, de Glas NA, et al
    Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.
    Eur J Cancer. 2018;99:1-8.
    PubMed     Abstract available


  126. MILLS MN, Yang GQ, Oliver DE, Liveringhouse CL, et al
    Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
    Eur J Cancer. 2018;98:48-58.
    PubMed     Abstract available


    May 2018
  127. LUND E, Nakamura A, Thalabard JC
    Re: No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer Study.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30773.
    PubMed    


  128. ZAHL PH
    Letter comments on EJC published paper: 'No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study'.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30774.
    PubMed    


  129. CRISCITIELLO C, Golshan M, Barry WT, Viale G, et al
    Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis.
    Eur J Cancer. 2018;97:1-6.
    PubMed     Abstract available


    April 2018
  130. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    PubMed     Abstract available


  131. GOBBINI E, Ezzalfani M, Dieras V, Bachelot T, et al
    Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Eur J Cancer. 2018;96:17-24.
    PubMed     Abstract available


  132. MAKAMA M, Drukker CA, Rutgers EJT, Slaets L, et al
    Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint((R)))" [Eur J Cancer 75 (April 2017) 5-13].
    Eur J Cancer. 2018 Apr 12. pii: S0959-8049(18)30747.
    PubMed    


  133. JACQUET E, Lardy-Cleaud A, Pistilli B, Franck S, et al
    Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Eur J Cancer. 2018;95:93-101.
    PubMed     Abstract available


  134. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Eur J Cancer. 2018;95:59-67.
    PubMed     Abstract available


  135. PLOQUIN A, Pistilli B, Tresch E, Frenel JS, et al
    5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Eur J Cancer. 2018;95:30-37.
    PubMed     Abstract available


    March 2018
  136. RUIZ A, van Hillegersberg R, Siesling S, Castro-Benitez C, et al
    Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison.
    Eur J Cancer. 2018;95:1-10.
    PubMed     Abstract available


  137. ROBERTSON JFR, Cheung KL, Noguchi S, Shao Z, et al
    Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2018;94:206-215.
    PubMed     Abstract available


  138. ETHIER JL, Ocana A, Rodriguez Lescure A, Ruiz A, et al
    Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
    Eur J Cancer. 2018;94:199-205.
    PubMed     Abstract available


  139. LINDMAN H, Andersson M, Ahlgren J, Balslev E, et al
    A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
    Eur J Cancer. 2018;94:79-86.
    PubMed     Abstract available


  140. WILSON C, Bell R, Hinsley S, Marshall H, et al
    Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.
    Eur J Cancer. 2018;94:70-78.
    PubMed     Abstract available


    February 2018
  141. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
    A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
    Eur J Cancer. 2018;93:19-27.
    PubMed     Abstract available


  142. LOKE SY, Lee ASG
    The future of blood-based biomarkers for the early detection of breast cancer.
    Eur J Cancer. 2018;92:54-68.
    PubMed     Abstract available


  143. AUTIER P, Boniol M
    Mammography screening: A major issue in medicine.
    Eur J Cancer. 2018;90:34-62.
    PubMed     Abstract available


    January 2018
  144. RAPHAEL J, Desautels D, Pritchard KI, Petkova E, et al
    Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2018;91:38-46.
    PubMed     Abstract available


  145. BRIER MJ, Chambless DL, Chen J, Mao JJ, et al
    Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31485.
    PubMed     Abstract available


    December 2017
  146. DACKUS GMHE, Jozwiak K, Sonke GS, van der Wall E, et al
    Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Eur J Cancer. 2017;90:92-101.
    PubMed     Abstract available


  147. ANDERSON JJ, Darwis NDM, Mackay DF, Celis-Morales CA, et al
    Red and processed meat consumption and breast cancer: UK Biobank cohort study and meta-analysis.
    Eur J Cancer. 2017;90:73-82.
    PubMed     Abstract available


  148. STRASSER-WEIPPL K, Sudan G, Ramjeesingh R, Shepherd LE, et al
    Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
    Eur J Cancer. 2017;90:19-25.
    PubMed     Abstract available


  149. LUND E, Nakamura A, Thalabard JC
    No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study.
    Eur J Cancer. 2017;89:102-112.
    PubMed     Abstract available


  150. NIXON NA, Hannouf MB, Verma S
    A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer.
    Eur J Cancer. 2017;89:72-81.
    PubMed     Abstract available


  151. FUJII T, Matsuda N, Kono M, Harano K, et al
    Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.
    Eur J Cancer. 2017;89:64-71.
    PubMed     Abstract available


  152. BOTTERI E, Krendyukov A, Curigliano G
    Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Eur J Cancer. 2017;89:49-55.
    PubMed     Abstract available


  153. DI COSIMO S, Campbell C, Azim HA Jr, Galli G, et al
    The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.
    Eur J Cancer. 2017;89:42-48.
    PubMed     Abstract available


  154. TONG Y, Chen X, Fei X, Lin L, et al
    Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?
    Eur J Cancer. 2017;89:9-18.
    PubMed     Abstract available


  155. SCHNEEWEISS A, Chia S, Hickish T, Harvey V, et al
    Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positiv
    Eur J Cancer. 2017;89:27-35.
    PubMed     Abstract available


  156. HOLM-RASMUSSEN EV, Jensen MB, Balslev E, Kroman N, et al
    The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.
    Eur J Cancer. 2017;87:1-9.
    PubMed     Abstract available


    November 2017
  157. DUFFY SW, Morrish OWE, Allgood PC, Black R, et al
    Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer.
    Eur J Cancer. 2017;88:48-56.
    PubMed     Abstract available


  158. MUSOLINO A, Falcini F, Sikokis A, Boggiani D, et al
    Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
    Eur J Cancer. 2017;88:10-20.
    PubMed     Abstract available


  159. MARTIN TA, Watkins G, Mansel RE, Jiang WG, et al
    Corrigendum to "Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer" [Eur J Cancer 40 (18) (2004) 2717-2725].
    Eur J Cancer. 2017 Nov 23. pii: S0959-8049(17)31384.
    PubMed    


  160. MILES D, Cameron D, Hilton M, Garcia J, et al
    Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.
    Eur J Cancer. 2017 Nov 23. pii: S0959-8049(17)31358.
    PubMed    


  161. CRISCITIELLO C, Bagnardi V, Pruneri G, Vingiani A, et al
    Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.
    Eur J Cancer. 2017;87:164-171.
    PubMed     Abstract available


  162. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    PubMed     Abstract available


  163. FORISSIER V, Tallet A, Cohen M, Classe JM, et al
    Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort.
    Eur J Cancer. 2017;87:47-57.
    PubMed     Abstract available


  164. LE RHUN E, Bertrand N, Dumont A, Tresch E, et al
    Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Eur J Cancer. 2017 Nov 2. pii: S0959-8049(17)31346.
    PubMed     Abstract available


  165. DAROLES J, Borget I, Suciu V, Mazouni C, et al
    Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?
    Eur J Cancer. 2017;85:23-30.
    PubMed     Abstract available


  166. VAN DAM PA, Tomatis M, Marotti L, Heil J, et al
    Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.
    Eur J Cancer. 2017;85:15-22.
    PubMed     Abstract available


    October 2017
  167. PARK YH, Im SA, Kim SB, Sohn JH, et al
    Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Eur J Cancer. 2017;86:385-393.
    PubMed     Abstract available


  168. BIGANZOLI E, Desmedt C, Fornili M, de Azambuja E, et al
    Recurrence dynamics of breast cancer according to baseline body mass index.
    Eur J Cancer. 2017;87:10-20.
    PubMed     Abstract available


  169. VAN MAAREN MC, van Steenbeek CD, Pharoah PDP, Witteveen A, et al
    Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
    Eur J Cancer. 2017;86:364-372.
    PubMed     Abstract available


  170. MULLOOLY M, Murphy J, Gierach GL, Walsh PM, et al
    Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.
    Eur J Cancer. 2017;86:326-333.
    PubMed     Abstract available


  171. TANG SS, Kaptanis S, Haddow JB, Mondani G, et al
    Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland.
    Eur J Cancer. 2017;84:315-324.
    PubMed     Abstract available


  172. STROM T, Harrison LB, Giuliano AR, Schell MJ, et al
    Tumour radiosensitivity is associated with immune activation in solid tumours.
    Eur J Cancer. 2017;84:304-314.
    PubMed     Abstract available


  173. DE NONNEVILLE A, Goncalves A, Zemmour C, Cohen M, et al
    Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    Eur J Cancer. 2017;84:34-43.
    PubMed     Abstract available


    September 2017
  174. PIVOT X, Verma S, Fallowfield L, Muller V, et al
    Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Eur J Cancer. 2017;86:82-90.
    PubMed     Abstract available


  175. BIGANZOLI L, Marotti L, Hart CD, Cataliotti L, et al
    Quality indicators in breast cancer care: An update from the EUSOMA working group.
    Eur J Cancer. 2017;86:59-81.
    PubMed     Abstract available


  176. GUERIN M, Rezai K, Isambert N, Campone M, et al
    PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Eur J Cancer. 2017;86:28-36.
    PubMed     Abstract available


  177. RAPHAEL J, Helou J, Pritchard KI, Naimark DM, et al
    Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Eur J Cancer. 2017;85:146-154.
    PubMed     Abstract available


  178. LOIBL S, de la Pena L, Nekljudova V, Zardavas D, et al
    Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    Eur J Cancer. 2017;85:133-145.
    PubMed     Abstract available


  179. MUCHOWICZ A, Wachowska M, Stachura J, Tonecka K, et al
    Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.
    Eur J Cancer. 2017;83:19-27.
    PubMed     Abstract available


  180. XIE ZM, Sun J, Hu ZY, Wu YP, et al
    Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy.
    Eur J Cancer. 2017;82:6-15.
    PubMed     Abstract available


  181. LAVOIE JM, Gelmon KA
    Getting under the skin.
    Eur J Cancer. 2017;82:228-229.
    PubMed    


    August 2017
  182. SIMIN J, Tamimi R, Lagergren J, Adami HO, et al
    Menopausal hormone therapy and cancer risk: An overestimated risk?
    Eur J Cancer. 2017;84:60-68.
    PubMed     Abstract available


    January 2017
  183. WU H, Wang D, Ruan X
    Physical activity and survival in breast cancer: What were missing?
    Eur J Cancer. 2017;71:121-122.
    PubMed    


  184. AMMITZBOLL G, Sogaard K, Karlsen RV, Tjonneland A, et al
    Reply to the letter: 'Physical activity and survival in breast cancer: What were missing?' by Wu H, Wang D, and Ruan X.
    Eur J Cancer. 2017;71:123-124.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: